A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
At a glance
- Drugs KX 02 (Primary)
- Indications Brain metastases; Cancer; Glioma
- Focus Adverse reactions; First in man
- Sponsors Athenex
- 24 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Jun 2018.
- 24 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2018.
- 24 Oct 2017 Status changed from recruiting to active, no longer recruiting.